Regulus Therapeutics (NASDAQ:RGLS) had its price target hoisted by HC Wainwright from $1.50 to $2.00 in a research report report published on Friday, The Fly reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.
Separately, Zacks Investment Research cut Regulus Therapeutics from a buy rating to a hold rating in a research report on Wednesday, May 12th.
Regulus Therapeutics stock opened at $0.88 on Friday. The stock has a market cap of $65.93 million, a PE ratio of -1.17 and a beta of 2.41. The stock has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.22. Regulus Therapeutics has a 52 week low of $0.42 and a 52 week high of $2.32.
Institutional investors and hedge funds have recently bought and sold shares of the business. Focused Wealth Management Inc purchased a new stake in Regulus Therapeutics in the 1st quarter valued at about $156,000. Renaissance Technologies LLC acquired a new position in shares of Regulus Therapeutics in the 4th quarter valued at about $606,000. Grimes & Company Inc. lifted its stake in shares of Regulus Therapeutics by 127.1% in the 4th quarter. Grimes & Company Inc. now owns 54,511 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 30,513 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Regulus Therapeutics in the 4th quarter valued at about $675,000. Finally, GYL Financial Synergies LLC acquired a new position in shares of Regulus Therapeutics in the 4th quarter valued at about $69,000. Institutional investors own 19.96% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease.
Featured Story: Understanding Market Liquidity
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.